Simos Simeonidis

Simos Simeonidis is currently Managing Partner at Kos Biotechnology Partners LLC.
Former positions include Co-CEO & Co-CIO at Ally Bridge Group HK Ltd (2022–2023), Co-Chief Executive & Investment Officer at Ally Bridge Group (NY) LLC (2022–2023), Independent Director at Regulus Therapeutics, Inc. (2019–2022), Senior Managing Director & Partner at Sarissa Capital Acquisition Corp.
(2017–2021), Managing Director at Royal Bank of Canada (New York Branch) (2014–2017), Analyst at RBC Capital Markets LLC (2014–2017), Managing Director & Senior Biotech Analyst at Cowen & Co. LLC (2011–2014), Managing Director & Senior Biotech Analyst at Rodman & Renshaw LLC (2011), Vice President & Senior Biotech Analyst at Broadpoint.
Gleacher Securities (2007–2008), Associate Biotech Analyst at Morgan Stanley & Co. LLC (2006), Associate Director at Novartis Corp.
(2005), and Member at Harvard Medical School (2001–2003).
Education includes an undergraduate degree from Loyola University of Chicago (1993), an MBA from The Wharton School of the University of Pennsylvania (2005), and graduate and doctorate degrees from Columbia University College of Physicians & Surgeons.